The Heart: A Novel Gonadotrophin-Releasing Hormone Target
- 21 February 2011
- journal article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 23 (5), 456-463
- https://doi.org/10.1111/j.1365-2826.2011.02119.x
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Treament-related diabetes and cardiovascular disease in prostate cancer survivorsPublished by Elsevier BV ,2008
- Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular MortalityJNCI Journal of the National Cancer Institute, 2007
- Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer, 2007
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Hormone therapy in men—increased risk of cardiac allograft rejection?The Journal of Heart and Lung Transplantation, 2003
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressureJournal of Human Hypertension, 2000
- Identity of Prolactin Inhibiting Factor (PIF) and Luteinizing Hormone-Releasing Factor (LRF).Experimental Biology and Medicine, 1964